Trial ID or NCT#
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
A Phase II Trial of Dasatinib in Advanced Sarcomas
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office